Develops DNA damage response cancer therapeutics, with lead candidate ART4215 in Phase I trials for solid tumours.
This profile is maintained by the Sesamers data desk. Claim it to edit details, post jobs and answer interviews.
€105,800,000
Total raised
-
Valuation
130
Employees
2016
Founded
Latest round
Series D+ - November 17, 2025
Series D+ - €105,800,000
November 17, 2025 · Read the story
✓ verified by our desk
Open roles
Artios is not hiring through Sesamers right now.
Work here? Claim the profile and post roles.
Claim your profile